.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Baxter
Johnson and Johnson
Colorcon
Fuji
Deloitte
Mallinckrodt
Chubb
McKinsey
Covington

Generated: November 17, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019892

« Back to Dashboard
NDA 019892 describes DILAUDID, which is a drug marketed by Fresenius Kabi Usa and Rhodes Pharms and is included in three NDAs. It is available from six suppliers. There is one patent protecting this drug and four Paragraph IV challenges. Additional details are available on the DILAUDID profile page.

The generic ingredient in DILAUDID is hydromorphone hydrochloride. There are fourteen drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the hydromorphone hydrochloride profile page.

Summary for 019892

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Analgesics
Formulation / Manufacturing:see details

Pharmacology for NDA: 019892

Mechanism of ActionFull Opioid Agonists

Medical Subject Heading (MeSH) Categories for 019892

Suppliers and Packaging for NDA: 019892

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DILAUDID
hydromorphone hydrochloride
TABLET;ORAL 019892 NDA AUTHORIZED GENERIC STAT RX USA LLC 16590-774 16590-774-30 30 TABLET in 1 BOTTLE (16590-774-30)
DILAUDID
hydromorphone hydrochloride
TABLET;ORAL 019892 NDA AUTHORIZED GENERIC STAT RX USA LLC 16590-774 16590-774-60 60 TABLET in 1 BOTTLE (16590-774-60)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength8MG
Approval Date:Dec 7, 1992TE:ABRLD:Yes
Patent:► SubscribePatent Expiration:Nov 9, 2020Product Flag?YSubstance Flag?YDelist Request?

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength4MG
Approval Date:Nov 9, 2007TE:ABRLD:Yes
Patent:► SubscribePatent Expiration:Nov 9, 2020Product Flag?YSubstance Flag?YDelist Request?

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength2MG
Approval Date:Nov 9, 2007TE:ABRLD:Yes
Patent:► SubscribePatent Expiration:Nov 9, 2020Product Flag?YSubstance Flag?YDelist Request?


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Daiichi Sankyo
Cantor Fitzgerald
US Army
Baxter
Colorcon
Moodys
QuintilesIMS
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot